RXRX (Recursion Pharmaceuticals) Moat Score: 5/10 (As of Jul. 07, 2026)


RXRX Recursion Pharmaceuticals Inc RXRX
77 GF Score
Price $3.96
GF Value $4.14
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Recursion Pharmaceuticals Moat Score?

Recursion Pharmaceuticals RXRX +4.21% 77 Moat Score is 5 as of Jul. 07, 2026. GuruFocus rates RXRX with a GF Score™ of 77/100 and a GF Value™ of $4.14 (Fairly Valued). The stock has 4 warning signs investors should review. Among 1,394 Biotechnology companies, Recursion Pharmaceuticals ranks better than 96.7% on this metric.

Recursion Pharmaceuticals has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

Recursion Pharmaceuticals has Narrow Moat: Recursion Pharmaceuticals Inc has valuable intellectual property and strong R&D capabilities in drug discovery. However, the competitive biotech landscape and limited market share restrict its moat to a solid narrow category.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Recursion Pharmaceuticals might have Narrow Moat - Solid narrow moat.

Recursion Pharmaceuticals  (NAS:RXRX) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Recursion Pharmaceuticals Moat Score Related Terms

RXRX vs ABSI, GLUE, ANAB: Moat Score Comparison

For the Biotechnology subindustry, Recursion Pharmaceuticals's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Recursion Pharmaceuticals Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Recursion Pharmaceuticals's Moat Score distribution charts can be found below:

* The bar in red indicates where Recursion Pharmaceuticals's Moat Score falls into.


RXRX
77GF Score
Recursion Pharmaceuticals Inc RXRX
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
Recursion Pharmaceuticals (RXRX) has a Moat Score of 5 as of Jul. 07, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Recursion Pharmaceuticals ranks #46 out of 1394 companies in the Biotechnology industry, placing it in the top 3.3%.
Is Recursion Pharmaceuticals' Moat Score too high?
Recursion Pharmaceuticals' current Moat Score is 5. The Biotechnology industry median Moat Score is 2.00. Recursion Pharmaceuticals' value of 5 is 150% above this industry median. Based on the distribution chart, Recursion Pharmaceuticals ranks #46 out of 1394 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Recursion Pharmaceuticals has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Recursion Pharmaceuticals' Moat Score compare to ABSI and GLUE?
According to the Biotechnology industry distribution chart, Recursion Pharmaceuticals ranks #46 out of 1394 companies for Moat Score. This places Recursion Pharmaceuticals in the top 3% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Recursion Pharmaceuticals' value of 5 is 150% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,394 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Recursion Pharmaceuticals's current Moat Score of 5 is 150% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Recursion Pharmaceuticals's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Recursion Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Recursion Pharmaceuticals (RXRX) is currently considered Fairly Valued. The stock's GF Value™ is $4.14, compared to a current price of $3.96 — trading 4.3% below its estimated fair value. The current Moat Score is 5 and 150% above the Biotechnology industry median of 2.00. Recursion Pharmaceuticals' overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Recursion Pharmaceuticals (RXRX), the current Moat Score is 5 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Recursion Pharmaceuticals (RXRX) Overvalued in 2026?

Based on GuruFocus' analysis, Recursion Pharmaceuticals stock appears to be undervalued. The current stock price of $3.96 is trading 4.3% below its estimated GF Value™ of $4.14. GuruFocus considers Recursion Pharmaceuticals to be Fairly Valued.

Key valuation signals for RXRX:

  • Moat Score: 5
  • GF Value™: $4.14 vs. price of $3.96 (4.3% below fair value)
  • GF Score™: 77/100 with 4 warning signs
  • Industry Position: 150% above the Biotechnology median (#46 of 1394)

No single metric tells the full story. See the RXRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Recursion Pharmaceuticals Business Description

Other Exchanges RXRX:Mexico
Address 41 South Rio Grande Street, Salt Lake City, UT, USA, 84101
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.
77GF Score

Get the complete analysis for RXRX

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.96
Price
$4.14
GF Value